17,261 trials
Systemic Lupus Erythematosus
Primary: Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) — 53.3…
Adenocarcinoma of the Lung · Non-small Cell Lung Cancer
Primary: Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I) — 0; 0; 0; 0 Number of DLTs seen
Cannabis Dependence
Primary: Percentage of Negative Urine Cannabinoid Tests During Treatment — 40.9; 27.2 percentage of negative urine tests — p=0.029
Non-Hodgkin's Lymphoma · Hodgkin's Lymphoma · Multiple Myeloma
Primary: Number of Participants With a Clinically Significant Infection — 12; 14; 5 Participants
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After the End of Treatment (SVR 12) — 100; 88 percentage of participants
Traumatic Brain Injury With Brief Loss of Consciousness · Post-Concussion Syndrome
Primary: Summary of Treatment-Emergent Adverse Events — 13; 5; 5; 3 Participants
Untreated Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS): Time to Event — 221; 213; 361; 337 days
Advanced Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 7.69; 7.75 months — p=0.248
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: The Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 0; 1 participants
Indolent Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 59.7 percentage of participants — p=<=0.0001
Leukemia · Lymphoma
Primary: Maximum Tolerated Dose — 1.8; 1.5 mg/m^2 of Bortezomib
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs) - Solicited and Unsolicited — 32; 30; 24; 27 Participants
Cystic Fibrosis
Primary: Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture — 2; 3 Participants
Atopic Dermatitis
Primary: Maximum Observed Plasma Concentration (Cmax) of MM36 — 23.1 ng/mL
Leukemia
Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants